Research

11 June, 2018

First Patient Dosed with Dystrophic Epidermolysis Bullosa Treatment, KB103

Krystal Biotech have announced that the first patient has been dosed in the Phase 1/2 clinical trial of its drug, KB103, for the treatment of dystrophic epidermolysis bullosa (DEB). The Phase 1/2 trial at Stanford University is a single-centre, open-label, placebo-controlled study conducting an intra-subject comparison...

11 June, 2018

CU Anschutz scientists awarded $3.8 million Department of Defense grant

In 2016, together with two other US based medical research charities, we funded the EB iPS Cell Consortium, which includes researchers from leading universities in the US. The results of its early work were so promising that it leveraged a major grant of $3.8 million,...

18 December, 2015

BBC News – The promise of gene editing

Sharmila Nikapota, the mother of a child with a rare genetic disorder, has high hopes for gene editing...

→